聚二乙醇化干扰素α对慢性乙肝患者的肝细胞脂肪变性影响

肝胆速递

http://www.ncbi.nlm.nih.gov/pubmed/22964150##
Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):285-8. doi: 10.3760/cma.j.issn.1007-3418.2012.04.012.
[Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B].
[Article in Chinese]
Shi JP, Lu L, Qian JC, Ang J, Xun YH, Guo JC, Shi WL, Wang YF, Fan JG.
Source

Hangzhou Sixth People's Hospital, Zhejiang University of Traditional Chinese Medicine, Hangzhou 310014 China.
Abstract
OBJECTIVE:

To investigate the impact of hepatic steatosis on virologic response in chronic hepatitis B (CHB) patients treated with pegylated interferon-alpha (PEG-IFNa).
METHODS:

Ninety-six naive patients positive for hepatitis B e antigen (HBeAg) and with biopsy-proven CHB were administered PEG-IFNa-2a or PEG-IFNa-2b for 48 weeks. Virologic response (HBeAg clearance and hepatitis B virus (HBV) DNA less than 5 log10 copies/ml) and biochemical response (alanine transaminase (ALT) normalization) were compared between patients with (n=34) and without (n=62) steatosis.
RESULTS:

The HBV DNA titer in the steatosis group was significantly lower than that of the non-steatosis group (6.961.27 vs. 7.541.28 log10 copies/ml; t=2.161, P=0.033). After 48 weeks of PEG-IFNa treatments, there was no significant difference in HBeAg seroconversion or the percentage of undetectable HBV DNA (less than 3 log10 copies/ml) between steatosis and non-steatosis patients. However, the steatosis patients presented with a significantly lower complete response rate (virologic response plus biochemical response) compared to non-steatosis patients (26.5% vs. 48.4%; x² =4.373, P=0.037). Of the 45 CHB patients with undetectable HBV DNA after 48 weeks of treatment, seven did not achieve ALT normalization. The rate of patients with non-biochemical response was significantly higher in the steatosis group than in the non-steatosis group (33.3% vs. 6.67%; P=0.032).
CONCLUSION:

Hepatic steatosis does not affect the virologic response, but does affect the biochemical response in CHB patients treated with PEG-IFNa for 48 weeks.

肝胆速递

中华肝脏病杂志。 2012年4月，20（4）:285-8。 DOI：10.3760/cma.j.issn.1007-3418.2012.04.012。
[抗病毒活性的聚乙二醇化干扰素-α与慢性B型肝炎患者的肝细胞脂肪变性的影响。
[中国]
郭迅YH，JP石，卢ł，钱JC，李安J，JC时，WL，王韫芳，范JG。
源

杭州市第六人民医院，浙江大学，中国传统医学，中国杭州310014。
抽象
目的：

探讨影响脂肪肝的病毒学应答的慢性乙型肝炎（CHB）患者与聚乙二醇化干扰素α（PEG-IFNa的）。
方法：

96个幼稚的B型肝炎e抗原（HBeAg）阳性患者，经活检证实的CHB给予PEG-IFNa的-2a或PEG-IFNa的-2B为48周。病毒学应答（HBeAg清除乙肝病毒（HBV）DNA小于5 log10拷贝/毫升）生化反应（谷丙转氨酶（ALT）正常化），比较患者（n = 34人）和组（n = 62）脂肪变性。
结果：

脂肪变性组的HBV DNA滴度显着低于非的脂肪变性集团（6.961.27  -  7.541.28 log10拷贝/ ml，T = 2.161，P = 0.033）。经过48周的PEG-IFNa的治疗，HBeAg血清学转换或脂肪肝和非脂肪变性的患者检测不到HBV DNA（小于3 log10拷贝/ ml）之间的比例没有显着差异。然而，脂肪变性患者具有显著较低的完全缓解率（病毒学应答加生化反应）相比，非脂肪变性的患者（26.5％比48.4％; X²= 4.373，P = 0.037）。在45例慢性乙型肝炎患者48周的治疗后，HBV DNA检测不到，七没有达到ALT正常化。的患者与非生化反应的速度是明显的脂肪变性组高比非脂肪变性组（33.3％对6.67％，P = 0.032）。
结论：

肝脂肪变性不影响病毒学应答，但不会影响PEG-IFNa的治疗慢性乙型肝炎患者48周的生化反应。

咬牙硬挺

感谢分享

lin12345

lin12345

大力支持好文章